Search research articles
Contact Us
Filters
Showing results (1-10 of 8) with videos related to
Page
of 1
Sort By:
Neurology
|
February 21, 2007
Steroid dementia: a follow-up
Oliver Sacks, Melanie Shulman
Neurology
|
February 25, 2005
Steroid dementia: an overlooked diagnosis?
Oliver Sacks, Melanie Shulman
Dementia and Geriatric Cognitive Disorders
|
January 26, 2017
Comprehensive, Individualized, Person-Centered Management of Community-Residing Persons with Moderate-to-Severe Alzheimer Disease: A Randomized Controlled Trial
Barry Reisberg, Yongzhao Shao, James Golomb, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
January 3, 2025
Understanding recent advances in non-amyloid/non-tau (NANT) biomarkers and therapeutic targets in Alzheimer's disease
Linda J Van Eldik, Eric R Siemers, Emily C Collins, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 25, 2025
Drug Development
Melanie Shulman, Shuang Wu, Jing Xie, et al.
Nature Aging
|
November 27, 2023
TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer's disease
Melanie Shulman, Jessica Kong, John O'Gorman, et al.
Nature Aging
|
February 11, 2026
Exploratory analyses of clinical outcomes from the BIIB080 phase 1b study in mild Alzheimer's disease
Melanie Shulman, Shuang Wu, Nick Ziogas, et al.
JAMA Neurology
|
October 30, 2023
Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease: A Randomized Clinical Trial
Amanda L Edwards, Jessica A Collins, Candice Junge, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 8) with videos related to
Sort By:
Page
of 1
Neurology
|
February 21, 2007
Steroid dementia: a follow-up
Oliver Sacks, Melanie Shulman
Neurology
|
February 25, 2005
Steroid dementia: an overlooked diagnosis?
Oliver Sacks, Melanie Shulman
Dementia and Geriatric Cognitive Disorders
|
January 26, 2017
Comprehensive, Individualized, Person-Centered Management of Community-Residing Persons with Moderate-to-Severe Alzheimer Disease: A Randomized Controlled Trial
Barry Reisberg, Yongzhao Shao, James Golomb, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
January 3, 2025
Understanding recent advances in non-amyloid/non-tau (NANT) biomarkers and therapeutic targets in Alzheimer's disease
Linda J Van Eldik, Eric R Siemers, Emily C Collins, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 25, 2025
Drug Development
Melanie Shulman, Shuang Wu, Jing Xie, et al.
Nature Aging
|
November 27, 2023
TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer's disease
Melanie Shulman, Jessica Kong, John O'Gorman, et al.
Nature Aging
|
February 11, 2026
Exploratory analyses of clinical outcomes from the BIIB080 phase 1b study in mild Alzheimer's disease
Melanie Shulman, Shuang Wu, Nick Ziogas, et al.
JAMA Neurology
|
October 30, 2023
Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease: A Randomized Clinical Trial
Amanda L Edwards, Jessica A Collins, Candice Junge, et al.
Page
of 1